Citations (200)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (18)
Scott F. Huntington, Sunita D. Nasta, Stephen J. Schuster, Jalpa A. Doshi & Jakub Svoboda. (2015) Utility of interim and end-of-treatment [18F]-fluorodeoxyglucose positron emission tomography–computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma 56:9, pages 2579-2584.
Read now
Read now
Karen Juul Mylam, Lale Kostakoglu, Martin Hutchings, Morton Coleman, Dominick Lamonica, Myron S. Czuczman, Louis F. Diehl, Anne L. Nielsen, Paw Jensen, Annika Loft, Helle W. Hendel, Victor Iyer, Sirpa Leppä, Sirkku Jyrkkiö, Harald Holte, Mikael Eriksson, Dorte Gillstrøm, Per B. Hansen, Marko Seppänen, Karin Hjorthaug, Peter de Nully Brown & Lars M. Pedersen. (2015) 18F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. Leukemia & Lymphoma 56:7, pages 2005-2012.
Read now
Read now
Maurizio Martelli, Alice Di Rocco, Eleonora Russo, Salvatore Perrone & Robin Foà. (2015) Primary mediastinal lymphoma: diagnosis and treatment options. Expert Review of Hematology 8:2, pages 173-186.
Read now
Read now
Karen J. Mylam, Tarec C. El-Galaly, Martin Hutchings, Peter Brown, Bodil Himmelstrup, Oke Gerke, Dorte Gillstrøm, Ida B. Sillesen, Lars Munksgaard, Bjarne B. Pedersen, Ilse Christiansen, Paw Jensen, Anne L. Nielsen & Lars M. Pedersen. (2014) Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. Leukemia & Lymphoma 55:7, pages 1563-1569.
Read now
Read now
Nathalie Nols, Nicolas Mounier, Salima Bouazza, Renaud Lhommel, Sabrina Costantini, Thierry Vander Borght, Marie-Christiane Vekemans, Anne Sonet, André Bosly, Lucienne Michaux, Marc André & Eric Van Den Neste. (2014) Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. Leukemia & Lymphoma 55:4, pages 773-780.
Read now
Read now
Kuruva Manohar, Bhagwant Rai Mittal, Senthil Raja, Anish Bhattacharya, Pankaj Malhotra & Subhash Varma. (2013) Comparison of various criteria in interpreting end of therapy F-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography in patients with aggressive non-Hodgkin lymphoma. Leukemia & Lymphoma 54:4, pages 714-719.
Read now
Read now
Eliza A. Hawkes, Andrew Wotherspoon & David Cunningham. (2012) The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management. Leukemia & Lymphoma 53:3, pages 354-361.
Read now
Read now
Tarec El-Galaly, Vineet Prakash, Ilse Christiansen, Jakob Madsen, Preben Johansen, Martin Boegsted, Hans-Erik Johnsen & Anne Bukh. (2011) Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. Leukemia & Lymphoma 52:4, pages 597-603.
Read now
Read now
N. George Mikhaeel. (2009) Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?. Leukemia & Lymphoma 50:12, pages 1931-1936.
Read now
Read now
Martin Hutchings. (2009) PET imaging in lymphoma. Expert Review of Hematology 2:3, pages 261-276.
Read now
Read now
Jinhua Zhao, Wenli Qiao, Chun Wang, Taisong Wang & Yan Xing. (2007) Therapeutic evaluation and prognostic value of interim hybrid PET/CT with 18F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma. Hematology 12:5, pages 423-430.
Read now
Read now
Lieselot Brepoels, Sigrid Stroobants, Walter De Wever, Karoline Spaepen, Peter Vandenberghe, Jose Thomas, Anne Uyttebroeck, Luc Mortelmans, Christiane De Wolf-Peeters & Gregor Verhoef. (2007) Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by Integrated International Workshop Criteria. Leukemia & Lymphoma 48:8, pages 1522-1530.
Read now
Read now
Lieselot Brepoels, Sigrid Stroobants, Walter de Wever, Karoline Spaepen, Peter Vandenberghe, Jose Thomas, Anne Uyttebroeck, Luc Mortelmans, Christiane de Wolf-Peeters & Gregor Verhoef. (2007) Hodgkin lymphoma: Response assessment by Revised International Workshop Criteria. Leukemia & Lymphoma 48:8, pages 1539-1547.
Read now
Read now
Bernd Kasper, Gerlinde Egerer, Martina Gronkowski, Sabine Haufe, Thomas Lehnert, Michael Eisenhut, Gunhild Mechtersheimer, Anthony D. Ho & Uwe Haberkorn. (2007) Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leukemia & Lymphoma 48:4, pages 746-753.
Read now
Read now
Marion Baudard, Frederic Comte, Anne Marie Conge, Denis Mariano-Goulart, Bernard Klein & Jean François Rossi. (2007) Importance of [18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma. Leukemia & Lymphoma 48:2, pages 381-388.
Read now
Read now
Lieselot Brepoels, Sigrid Stroobants & Gregor Verhoef. (2007) PET and PET/CT for response evaluation in lymphoma: Current practice and developments. Leukemia & Lymphoma 48:2, pages 270-282.
Read now
Read now
Lapo Alinari, Valentina Ambrosini, Paolo Castellucci, Monica Tani, Vittorio Stefoni, Cristina Nanni, Mohsen Farsad, Domenico Rubello, Roberto Franchi, Pier Luigi Zinzani & Stefano Fanti. (2006) Discordant response to chemotherapy: An unusual patternof fluoro-deoxy-d-glucose uptake in heavily pre-treated lymphoma patients. Leukemia & Lymphoma 47:6, pages 1048-1052.
Read now
Read now
Patrizia Chiusolo, Simona Sica & Giuseppe Leone. (2003) The Use of Positron Emission Tomography with [18F] 2-Fluoro-d-2-Deoxyglucose (FDG-PET) in Hodgkin and Non-Hodgkin's Lymphoma. Hematology 8:6, pages 403-408.
Read now
Read now
Articles from other publishers (182)
Naelle LOMBION, Philippe ROBIN, Adrian TEMPESCUL, Pierre-Yves LE ROUX, Ulrike SCHICK, Gaëlle GUILLERM, Jean-Christophe IANOTTO, Christian BERTHOU, Pierre-Yves SALAÜN & Ronan ABGRAL. (2022) Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria. The Quarterly Journal of Nuclear Medicine and Molecular Imaging 65:4.
Crossref
Crossref
Nicola M. Hughes, Heather A. Jacene, Sree Harsha Tirumani & Richard L. Wahl. 2020. Nuclear Oncology. Nuclear Oncology
1
45
.
Nicola M. Hughes, Heather A. Jacene, Sree Harsha Tirumani & Richard L. Wahl. 2022. Nuclear Oncology. Nuclear Oncology
431
474
.
N Ari Wijetunga, Brandon Stuart Imber, James F Caravelli, N George Mikhaeel & Joachim Yahalom. (2021) A picture is worth a thousand words: a history of diagnostic imaging for lymphoma. The British Journal of Radiology 94:1127.
Crossref
Crossref
Malik E. Juweid, Marguerite Mueller, Abdullah Alhouri, M. Ziad A‐Risheq & Felix M. Mottaghy. (2021) Positron emission tomography/computed tomography in the management of Hodgkin and B‐cell non‐Hodgkin lymphoma: An update. Cancer 127:20, pages 3727-3741.
Crossref
Crossref
Yu Ri Kim, Soo-Jeong Kim, June-Won Cheong, Yundeok Kim, Ji Eun Jang, Hyunsoo Cho, Haerim Chung, Yoo Hong Min, Woo Ick Yang, Arthur Cho & Jin Seok Kim. (2021) Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin’s lymphoma. The Korean Journal of Internal Medicine 36:Suppl 1, pages S245-S252.
Crossref
Crossref
N. George Mikhaeel, David Cunningham, Nicholas Counsell, Andrew McMillan, John A. Radford, Kirit M. Ardeshna, Anthony Lawrie, Paul Smith, Laura Clifton‐Hadley, Michael J. O'Doherty & Sally F. Barrington. (2020) FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study. British Journal of Haematology 192:3, pages 504-513.
Crossref
Crossref
Joseph A. Sparano, Jeannette Y. Lee, Lawrence D. Kaplan, Juan Carlos Ramos, Richard F. Ambinder, William Wachsman, David Aboulafia, Ariela Noy, David H. Henry, Lee Ratner, Ethel Cesarman, Amy Chadburn & Ronald Mitsuyasu. (2020) Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. Haematologica 106:3, pages 730-735.
Crossref
Crossref
Jan Maciej Zaucha, Stephane Chauvie, Renata Zaucha, Alberto Biggii & Andrea Gallamini. (2019) The role of PET/CT in the modern treatment of Hodgkin lymphoma. Cancer Treatment Reviews 77, pages 44-56.
Crossref
Crossref
Lale Kostakoglu & Grzegorz S. Nowakowski. (2019) End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma. PET Clinics 14:3, pages 307-315.
Crossref
Crossref
Paola Anna Erba, Martina Sollini, Roberto Boni & Sara Galimberti. 2019. Nuclear Medicine Textbook. Nuclear Medicine Textbook
655
705
.
Vicky Chin, Michael Fulham, Mark Hertzberg, Michael Jackson, Robert Lindeman, Timothy Brighton, Giselle Kidson-Gerber, Eva A Wegner, Carol Cheung, Susan MacCallum, Janet Williams & Stephen R Thompson. (2018) Impact of salvage treatment modalities in patients with positive FDG-PET/CT after R-CHOP chemotherapy for aggressive B-cell non-Hodgkin lymphoma. Journal of Medical Imaging and Radiation Oncology 62:3, pages 432-439.
Crossref
Crossref
Sally F. Barrington & Regine Kluge. (2017) FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. European Journal of Nuclear Medicine and Molecular Imaging 44:S1, pages 97-110.
Crossref
Crossref
Naveen M. KulkarniDaniella F. PinhoSrikala NarayananAvinash R. KambadakoneJeremy S. AbramsonDushyant V. Sahani. (2017) Imaging for Oncologic Response Assessment in Lymphoma. American Journal of Roentgenology 208:1, pages 18-31.
Crossref
Crossref
Chadwick L. Wright, Joseph J. Maly, Jun Zhang & Michael V. Knopp. (2017) Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma. PET Clinics 12:1, pages 63-82.
Crossref
Crossref
Heather A. Jacene, Sree Harsha Tirumani & Richard L. Wahl. 2017. Nuclear Oncology. Nuclear Oncology
353
393
.
Eun Ji Han, Joo Hyun O, Hyukjin Yoon, Seung Eun Jung, Gyeongsin Park, Byung Ock Choi & Seok-Goo Cho. (2016) FDG PET/CT response in diffuse large B-cell lymphoma. Medicine 95:39, pages e4983.
Crossref
Crossref
Ryogo Minamimoto, Luis Fayad, Ranjana Advani, Julie Vose, Homer Macapinlac, Jane Meza, Jordan Hankins, Felix Mottaghy, Malik Juweid & Andrew Quon. (2016) Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. Radiology 280:1, pages 220-229.
Crossref
Crossref
L. Valls, C. Badve, S. Avril, K. Herrmann, P. Faulhaber, J. O'Donnell & N. Avril. (2016) FDG-PET imaging in hematological malignancies. Blood Reviews 30:4, pages 317-331.
Crossref
Crossref
Wendy Atkinson, Ciprian Catana, Jeremy S. Abramson, Grae Arabasz, Shanaugh McDermott, Onofrio Catalano, Victorine Muse, Michael A. Blake, Jeffrey Barnes, Martin Shelly, Ephraim Hochberg, Bruce R. Rosen & Alexander R. Guimaraes. (2016) Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients. Abdominal Radiology 41:7, pages 1338-1348.
Crossref
Crossref
N. George Mikhaeel, Daniel Smith, Joel T. Dunn, Michael Phillips, Henrik Møller, Paul A. Fields, David Wrench & Sally F. Barrington. (2016) Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. European Journal of Nuclear Medicine and Molecular Imaging 43:7, pages 1209-1219.
Crossref
Crossref
Franco CavalliLuca CerianiEmanuele Zucca. (2016) Functional Imaging Using 18-Fluorodeoxyglucose PET in the Management of Primary Mediastinal Large B-Cell Lymphoma: The Contributions of the International Extranodal Lymphoma Study Group. American Society of Clinical Oncology Educational Book:36, pages e368-e375.
Crossref
Crossref
S.H. Kwon, D.R. Kang, J. Kim, J.-K. Yoon, S.J. Lee, S.H. Jeong, H.W. Lee & Y.-S. An. (2016) Prognostic value of negative interim 2-[18F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma. Clinical Radiology 71:3, pages 280-286.
Crossref
Crossref
Heather A. Jacene, Sree Harsha Tirumani & Richard L. Wahl. 2016. Nuclear Oncology. Nuclear Oncology
1
42
.
Fernando Mendes, Cátia Domingues, Ricardo Teixo, Ana Margarida Abrantes, Ana Cristina Gonçalves, Inês Nobre-Gois, Miguel Jacobetty, Ana Bela Sarmento, Maria Filomena Botelho & Manuel Santos Rosa. (2015) The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review. Cancer and Metastasis Reviews 34:3, pages 511-525.
Crossref
Crossref
Martin Hutchings & Sally Barrington. (2015) FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma. Clinical and Translational Imaging 3:4, pages 271-281.
Crossref
Crossref
Israt S. Alam, Mubarik A. Arshad, Quang-Dé Nguyen & Eric O. Aboagye. (2015) Radiopharmaceuticals as probes to characterize tumour tissue. European Journal of Nuclear Medicine and Molecular Imaging 42:4, pages 537-561.
Crossref
Crossref
Deok-Hwan YangSung-Hoon JungJae-Sook AhnYeo-Kyeoung KimJung-Joon MinHee-Seung BomJe-Jung LeeHyeoung-Joon Kim. (2015) Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma. Chonnam Medical Journal 51:3, pages 109.
Crossref
Crossref
Mixue Xie, Kefei Wu, Yan Liu, Qi Jiang & Yanhui Xie. (2014) Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants. Medical Oncology 32:1.
Crossref
Crossref
Tarec Christoffer El-Galaly & Martin Hutchings. 2015. Non-Hodgkin Lymphoma. Non-Hodgkin Lymphoma
125
146
.
Robert Carr, Stefano Fanti, Diana Paez, Juliano Cerci, Tamás Györke, Francisca Redondo, Tim P. Morris, Claudio Meneghetti, Chirayu Auewarakul, Reena Nair, Charity Gorospe, June-Key Chung, Isinsu Kuzu, Monica Celli, Sumeet Gujral, Rose Ann Padua & Maurizio Dondi. (2014) Prospective International Cohort Study Demonstrates Inability of Interim PET to Predict Treatment Failure in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine 55:12, pages 1936-1944.
Crossref
Crossref
Thomas Knogler, Karem El-Rabadi, Michael Weber, Georgios Karanikas & Marius E. Mayerhoefer. (2014) Three-dimensional texture analysis of contrast enhanced CT images for treatment response assessment in Hodgkin lymphoma: Comparison with F-18-FDG PET. Medical Physics 41:12, pages 121904.
Crossref
Crossref
R. Vaidya & T.E. Witzig. (2014) Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Annals of Oncology 25:11, pages 2124-2133.
Crossref
Crossref
Karen Juul Mylam, Anne Lerberg Nielsen, Lars Møller Pedersen & Martin Hutchings. (2014) Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma. PET Clinics 9:4, pages 443-455.
Crossref
Crossref
Sally F. BarringtonN. George MikhaeelLale KostakogluMichel MeignanMartin HutchingsStefan P. MüellerLawrence H. SchwartzEmanuele ZuccaRichard I. FisherJudith TrotmanOtto S. HoekstraRodney J. HicksMichael J. O'DohertyRoland HustinxAlberto BiggiBruce D. Cheson. (2014) Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology 32:27, pages 3048-3058.
Crossref
Crossref
Benjapa Khiewvan, Homer A. Macapinlac, Dina Lev, Ian E. McCutcheon, John M. Slopis, Ghadah Al Sannaa, Wei Wei & Hubert H. Chuang. (2014) The value of 18F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors. European Journal of Nuclear Medicine and Molecular Imaging 41:9, pages 1756-1766.
Crossref
Crossref
Maurizio MartelliLuca CerianiEmanuele ZuccaPier Luigi ZinzaniAndrés J.M. FerreriUmberto VitoloCaterina StelitanoErcole BrusamolinoMaria Giuseppina CabrasLuigi RigacciMonica BalzarottiFlavia SalviSilvia MontotoArmando Lopez-GuillermoErica FinolezziStefano A. PileriAndrew DaviesFranco CavalliLuca GiovanellaPeter W.M. Johnson. (2014)
[
18
F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study
. Journal of Clinical Oncology 32:17, pages 1769-1775.
Crossref
Crossref
Rosj Gallicchio, Giovanna Mansueto, Vittorio Simeon, Anna Nardelli, Roberto Guariglia, Daniela Capacchione, Ernesto Soscia, Piernicola Pedicini, Domenico Gattozzi, Pellegrino Musto & Giovanni Storto. (2014) F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. European Journal of Haematology 92:5, pages 382-389.
Crossref
Crossref
Lale Kostakoglu & Bruce D. Cheson. (2014) Current role of FDG PET/CT in lymphoma. European Journal of Nuclear Medicine and Molecular Imaging 41:5, pages 1004-1027.
Crossref
Crossref
É. Herin, J. Chalaye, J.-L. Lagrange, K. Belhadj, É. De Kerviler, A. Luciani, A. Rahmouni & E. Itti. 2014. Imagerie Post-Thérapeutique en Oncologie. Imagerie Post-Thérapeutique en Oncologie
265
298
.
Chieh Lin, Emmanuel Itti, Alain Luciani, Yenlin Huang, Corinne Haioun, Violaine Safar, Tzu-Chen Yen & Alain Rahmouni. 2014. Functional Imaging in Oncology. Functional Imaging in Oncology
1311
1334
.
Emmanuel Itti, Michel Meignan, Alina Berriolo-Riedinger, Alberto Biggi, Amanda F. Cashen, Pierre Véra, Hervé Tilly, Barry A. Siegel, Andrea Gallamini, René-Olivier Casasnovas & Corinne Haioun. (2013) An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax. European Journal of Nuclear Medicine and Molecular Imaging 40:9, pages 1312-1320.
Crossref
Crossref
Irit Avivi, Ariel Zilberlicht, Eldad J. Dann, Ronit Leiba, Tal Faibish, Jacob M. Rowe & Rachel Bar‐Shalom. (2013) Strikingly high false positivity of surveillance FDG‐PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. American Journal of Hematology 88:5, pages 400-405.
Crossref
Crossref
Silvia Fuertes, Xavier Setoain, Armando Lopez-Guillermo, Josep-Lluis Carrasco, Sonia Rodríguez, Jordina Rovira & Francesca Pons. (2013) Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging 40:4, pages 496-504.
Crossref
Crossref
Juliano Julio Cerci, Carlos Cunha Pereira Neto, Cassiano Krauzer, Danielle Giacometti Sakamoto & João Vicente Vitola. (2012) The impact of coaxial core biopsy guided by FDG PET/CT in oncological patients. European Journal of Nuclear Medicine and Molecular Imaging 40:1, pages 98-103.
Crossref
Crossref
Heather A. Jacene & Richard L. Wahl. 2013. Nuclear Oncology. Nuclear Oncology
153
187
.
Chris R. Kelsey & Lynn D. Wilson. 2014. Decision Tools for Radiation Oncology. Decision Tools for Radiation Oncology
257
278
.
Hubert H. Chuang, Ferhat Deniz, Kanishka Sircar, Camilo Jimenez, Carlos Rubin De Celis, Christopher G. Wood & Mouhammed Amir Habra. (2012)
[
18
F]Fluorodeoxyglucose Positron Emission Tomography–Guided Therapy in Metastatic Adrenocortical Carcinoma: An Illustrative Case
. Journal of Clinical Oncology 30:26, pages e246-e249.
Crossref
Crossref
A. Afshar-Oromieh, C. Kratochwil, U. Haberkorn & F.L. Giesel. (2012) Stellenwert der PET/CT in der LymphomdiagnostikImportance of PET/CT in lymphoma diagnostics. Der Radiologe 52:4, pages 338-346.
Crossref
Crossref
M. J. Shelly, S. McDermott, O. J. O'Connor & M. A. Blake. (2012) 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma. ISRN Hematology 2012, pages 1-9.
Crossref
Crossref
Craig Moskowitz. (2012) Diffuse large B Cell lymphoma: How can we cure more patients in 2012?. Best Practice & Research Clinical Haematology 25:1, pages 41-47.
Crossref
Crossref
Violaine SafarJehan DupuisEmmanuel IttiFabrice JardinChristophe FruchartStéphane BardetPierre VéraChristiane Copie-BergmanAlain RahmouniHervé TillyMichel MeignanCorinne Haioun. (2012)
Interim [
18
F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab
. Journal of Clinical Oncology 30:2, pages 184-190.
Crossref
Crossref
Shingo Baba, Koichiro Abe, Takuro Isoda, Yasuhiro Maruoka, Masayuki Sasaki & Hiroshi Honda. (2011) Impact of FDG-PET/CT in the management of lymphoma. Annals of Nuclear Medicine 25:10, pages 701-716.
Crossref
Crossref
F L Day, E Link, S Ngan, T Leong, K Moodie, C Lynch, M Michael, E de Winton, A Hogg, R J Hicks & A Heriot. (2011) FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. British Journal of Cancer 105:4, pages 498-504.
Crossref
Crossref
Ranjit Banwait, Kevin O'Regan, Federico Campigotto, Brianna Harris, Dilek Yarar, Meghan Bagshaw, Xavier Leleu, Renee Leduc, Nikhil Ramaiya, Edie Weller & Irene M. Ghobrial. (2011)
The role of
18
F‐FDG PET/CT imaging in Waldenstrom macroglobulinemia
. American Journal of Hematology 86:7, pages 567-572.
Crossref
Crossref
Deok-Hwan Yang, Jung-Joon Min, Ho-Chun Song, Yong Yeon Jeong, Woong-Ki Chung, Soo-Young Bae, Jae-Sook Ahn, Yeo-Kyeoung Kim, Hee-Seung Bom, Ik-Joo Chung, Hyeoung-Joon Kim & Je-Jung Lee. (2011) Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. European Journal of Cancer 47:9, pages 1312-1318.
Crossref
Crossref
Chieh Lin, Emmanuel Itti, Alain Luciani, Benhalima Zegai, Shih-jui Lin, Frédérique Kuhnowski, Frédéric Pigneur, Isabelle Gaillard, Gaetano Paone, Michel Meignan, Corinne Haioun & Alain Rahmouni. (2011) Whole-Body Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Treatment Response Assessment in Patients With Diffuse Large B-Cell Lymphoma. Investigative Radiology 46:5, pages 341-349.
Crossref
Crossref
Amanda F. Cashen, Farrokh Dehdashti, Jingqin Luo, Andrew Homb, Barry A. Siegel & Nancy L. Bartlett. (2011)
18
F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation
. Journal of Nuclear Medicine 52:3, pages 386-392.
Crossref
Crossref
X. Cahu, C. Bodet-Milin, E. Brissot, H. Maisonneuve, R. Houot, N. Morineau, P. Solal-Celigny, P. Godmer, T. Gastinne, P. Moreau, A. Moreau, T. Lamy, F. Kraber-Bodere & S. Le Gouill. (2011) 18F-fluorodeoxyglucose–positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. Annals of Oncology 22:3, pages 705-711.
Crossref
Crossref
Pier Luigi Zinzani, Letizia Gandolfi, Alessandro Broccoli, Lisa Argnani, Stefano Fanti, Cinzia Pellegrini, Vittorio Stefoni, Enrico Derenzini, Federica Quirini & Michele Baccarani. (2010)
Midtreatment
18
F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma
. Cancer 117:5, pages 1010-1018.
Crossref
Crossref
J.A. Dorth, J.P. Chino, L.R. Prosnitz, L.F. Diehl, A.W. Beaven, R.E. Coleman & C.R. Kelsey. (2011) The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG–PET or gallium-67 scans. Annals of Oncology 22:2, pages 405-410.
Crossref
Crossref
R.C. Delgado-Bolton & J.L. Carreras Delgado. (2011) Évaluation de la réponse au traitement du lymphome avec la TEP 18F-FDG : existe-t-il un consensus dans l’évaluation de la réponse ?. Médecine Nucléaire 35:1, pages 29-37.
Crossref
Crossref
Dominique Delbeke. 2011. Diseases of the Heart and Chest, Including Breast 2011–2014. Diseases of the Heart and Chest, Including Breast 2011–2014
193
198
.
Malik E. Juweid. 2011. Positron Emission Tomography. Positron Emission Tomography
1
19
.
Lale Kostakoglu. 2011. Clinical PET-CT in Radiology. Clinical PET-CT in Radiology
265
291
.
Emmanuel Itti, Malik E. Juweid, Corinne Haioun, Imene Yeddes, Fatma Hamza-Maaloul, Intidhar El Bez, Eva Evangelista, Chieh Lin, Jehan Dupuis & Michel Meignan. (2010)
Improvement of Early
18
F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background
. Journal of Nuclear Medicine 51:12, pages 1857-1862.
Crossref
Crossref
Sandip Basu. (2010) Personalized versus evidence-based medicine with PET-based imaging. Nature Reviews Clinical Oncology 7:11, pages 665-668.
Crossref
Crossref
C. Jackson, B. Sirohi, D. Cunningham, A. Horwich, K. Thomas & A. Wotherspoon. (2010) Lymphocyte-predominant Hodgkin lymphoma—clinical features and treatment outcomes from a 30-year experience. Annals of Oncology 21:10, pages 2061-2068.
Crossref
Crossref
Anne-Sophie Michallet, Judith Trotman & Christelle Tychyj-Pinel. (2010) Role of early PET in the management of diffuse large B-cell lymphoma. Current Opinion in Oncology 22:5, pages 414-418.
Crossref
Crossref
Pareen Shenoy, Rajni Sinha, John W. Tumeh, Mary Jo Lechowicz & Christopher Flowers. (2010) Surveillance Computed Tomography Scans for Patients With Lymphoma: Is the Risk Worth the Benefits?. Clinical Lymphoma Myeloma and Leukemia 10:4, pages 270-277.
Crossref
Crossref
Norbert Avril. 2010. Monoclonal Antibody and Peptide‐Targeted Radiotherapy of Cancer. Monoclonal Antibody and Peptide‐Targeted Radiotherapy of Cancer
527
542
.
Shao-li Song, Chuang Deng, Ling-feng Wen, Jian-jun Liu, Hui Wang, David Feng, Ching-yee Oliver Wong & Gang Huang. (2010) 18F-FDG PET/CT-related metabolic parameters and their value in early prediction of chemotherapy response in a VX2 tumor model. Nuclear Medicine and Biology 37:3, pages 327-333.
Crossref
Crossref
Xuan Canh Nguyen, Won Woo Lee, Amr Mohamed Amin, Jae Seon Eo, Soo-Mee Bang, Jong Seok Lee & Sang Eun Kim. (2010) Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma. Nuclear Medicine and Molecular Imaging 44:1, pages 39-44.
Crossref
Crossref
Juliano J. CerciEvelinda TrindadeLuís F. PracchiaFelipe A. PitellaCamila C.G. LinardiJosé SoaresJrJrDominique DelbekeLeigh-Ann TopferValeria BuccheriJosé C. Meneghetti. (2010) Cost Effectiveness of Positron Emission Tomography in Patients With Hodgkin's Lymphoma in Unconfirmed Complete Remission or Partial Remission After First-Line Therapy. Journal of Clinical Oncology 28:8, pages 1415-1421.
Crossref
Crossref
Angelika Bischof Delaloye. 2010. Diseases of the Abdomen and Pelvis 2010–2013. Diseases of the Abdomen and Pelvis 2010–2013
199
203
.
Yiyan Liu. (2009) Clinical significance of diffusely increased splenic uptake on FDG-PET. Nuclear Medicine Communications 30:10, pages 763-769.
Crossref
Crossref
Martin Hutchings & Sally F. Barrington. (2009) PET/CT for Therapy Response Assessment in Lymphoma. Journal of Nuclear Medicine 50:Suppl 1, pages 21S-30S.
Crossref
Crossref
K Hodby & P A Fields. (2009) Management of lymphoma in pregnancy. Obstetric Medicine 2:2, pages 46-51.
Crossref
Crossref
Deok-Hwan Yang, Jung-Joon Min, Yong Yeon Jeong, Jae-Sook Ahn, Yeo-Kyeoung Kim, Sang-Hee Cho, Ik-Joo Chung, Hee-Seung Bom, Hyeoung-Joon Kim & Je-Jung Lee. (2008) The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin’s lymphoma. Annals of Hematology 88:5, pages 425-432.
Crossref
Crossref
Pier Luigi ZinzaniVittorio StefoniMonica TaniStefano FantiGerardo MusuracaPaolo CastellucciEnrica MarchiMariapaola FinaValentina AmbrosiniCinzia PellegriniLapo AlinariEnrico DerenziniGiancarlo MontiniAlessandro BroccoliFrancesco BacciStefano PileriMichele Baccarani. (2009)
Role of [
18
F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma
. Journal of Clinical Oncology 27:11, pages 1781-1787.
Crossref
Crossref
Emmanuel Itti, Chieh Lin, Jehan Dupuis, Gaetano Paone, Daniela Capacchione, Alain Rahmouni, Corinne Haioun & Michel Meignan. (2009)
Prognostic Value of Interim
18
F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy
. Journal of Nuclear Medicine 50:4, pages 527-533.
Crossref
Crossref
Yang Yu, Jibin Liu & Lixue Yin. (2009) Application progress of lymphography in oncology. Frontiers of Medicine in China 3:1, pages 13-19.
Crossref
Crossref
H.S. Han, M.P. Escalón, B. Hsiao, A. Serafini & I.S. Lossos. (2009) High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Annals of Oncology 20:2, pages 309-318.
Crossref
Crossref
H. Hricak, J. Husband, D.M. Panicek & D. Dinter. 2009. Bildgebung in der Onkologie. Bildgebung in der Onkologie
175
185
.
Vitaliana De Sanctis, Erica Finolezzi, Mattia Falchetto Osti, Lavinia Grapulin, Marco Alfò, Edoardo Pescarmona, Francesca Berardi, Fiammetta Natalino, Maria Luisa Moleti, Alice Di Rocco, Riccardo Maurizi Enrici, Robin Foà & Maurizio Martelli. (2008) MACOP-B and Involved-Field Radiotherapy Is an Effective and Safe Therapy for Primary Mediastinal Large B Cell Lymphoma. International Journal of Radiation Oncology*Biology*Physics 72:4, pages 1154-1160.
Crossref
Crossref
Enrico Derenzini, Gerardo Musuraca, Stefano Fanti, Vittorio Stefoni, Monica Tani, Lapo Alinari, Filippo Venturini, Letizia Gandolfi, Michele Baccarani & Pier Luigi Zinzani. (2008) Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B‐cell non‐Hodgkin lymphoma. Cancer 113:9, pages 2496-2503.
Crossref
Crossref
Lale Kostakoglu. (2008) Early prediction of response to therapy: the clinical implications in Hodgkin’s and non-Hodgkin’s lymphoma. European Journal of Nuclear Medicine and Molecular Imaging 35:8, pages 1413-1420.
Crossref
Crossref
Alaa A. Muslimani, Timothy P. Spiro, Hamed A. Daw, Vincent C. Chan & Peter Bambakidis. (2008) Neurolymphomatosis: the challenge of diagnosis and treatment. Community Oncology 5:6, pages 339-341.
Crossref
Crossref
G. Moulin-Romsee, K. Spaepen, S. Stroobants & L. Mortelmans. (2008) Non-Hodgkin lymphoma: retrospective study on the cost-effectiveness of early treatment response assessment by FDG-PET. European Journal of Nuclear Medicine and Molecular Imaging 35:6, pages 1074-1080.
Crossref
Crossref
Martin Hutchings & Lena Specht. (2008) PET/CT in the management of haematological malignancies. European Journal of Haematology 80:5, pages 369-380.
Crossref
Crossref
Keisuke Enomoto, Kenichiro Hamada, Hidenori Inohara, Ichiro Higuchi, Yasuhiko Tomita, Takeshi Kubo & Jun Hatazawa. (2008) Mucosa-associated lymphoid tissue lymphoma studied with FDG-PET: a comparison with CT and endoscopic findings. Annals of Nuclear Medicine 22:4, pages 261-267.
Crossref
Crossref
Dimitrios Karantanis, Rathan M. Subramaniam, Patrick J. Peller, Val J. Lowe, Jolanta M. Durski, Douglas A. Collins, Evangelos Georgiou, Stephen M. Ansell & Gregory A. Wiseman. (2008) The Value of [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Extranodal Natural Killer/T—Cell Lymphoma. Clinical Lymphoma and Myeloma 8:2, pages 94-99.
Crossref
Crossref
Yvette L Kasamon & Richard L Wahl. (2008) FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Current Opinion in Oncology 20:2, pages 206-219.
Crossref
Crossref
Phillip H. Kuo, Bruce L. McClennan, Kacie Carlson, Lynn D. Wilson, Richard L. Edelson, Peter W. Heald & Michael Girardi. (2008) FDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma. Molecular Imaging and Biology 10:2, pages 74-81.
Crossref
Crossref
F.A. Hampson & A.S. Shaw. (2008) Response assessment in lymphoma. Clinical Radiology 63:2, pages 125-135.
Crossref
Crossref
Thomas C. Kwee, Robert M. Kwee & Rutger A. J. Nievelstein. (2008) Imaging in staging of malignant lymphoma: a systematic review. Blood 111:2, pages 504-516.
Crossref
Crossref
Siow Ming Lee, Tomas Buchler, Jamshed Bomanji, Alan Ramsay & Simon G Edwards. (2008) Thymic 18F-fluorodeoxyglucose uptake on positron emission tomography scanning after doxorubicin, bleomycin, vincristin and dacarbazine chemotherapy and highly-active antiretroviral therapy in HIV-associated Hodgkin's disease in an adult. AIDS 22:1, pages 159-160.
Crossref
Crossref
Teruhiko Terasawa, Takashi Nihashi, Tomomitsu Hotta & Hirokazu Nagai. (2008)
18
F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review
. Journal of Nuclear Medicine 49:1, pages 13-21.
Crossref
Crossref
Lale Kostakoglu. (2008) FDG-PET Evaluation of Response to Treatment. PET Clinics 3:1, pages 37-75.
Crossref
Crossref
Natia Esiashvili, Cynthia Anderson, Shannon T. Kahn & Raghuveer Halkar. 2008. PET-CT in Radiotherapy Treatment Planning. PET-CT in Radiotherapy Treatment Planning
185
203
.
Timothy S. Fenske & Nancy L. Bartlett. 2008. Pearson's Thoracic and Esophageal Surgery. Pearson's Thoracic and Esophageal Surgery
1622
1633
.
Michael Moore & Michael A. Blake. 2008. MDCT. MDCT
166
208
.
S. N. Reske. 2008. PET in Oncology. PET in Oncology
93
107
.
Ching-yee O Wong, Joseph Schmidt, Jeffery S Bong, Suyra Chundru, Larry Kestin, Di Yan, Inga Grills, Marianne Gaskill, Vincent Cheng, Alvaro A Martinez & Darlene Fink-Bennett. (2007) Correlating metabolic and anatomic responses of primary lung cancers to radiotherapy by combined F-18 FDG PET-CT imaging. Radiation Oncology 2:1.
Crossref
Crossref
Dimitrios Karantanis, Brian P. O'Neill, Rathan M. Subramaniam, Robert J. Witte, Brian P. Mullan, Mark A. Nathan, Val J. Lowe, Patrick J. Peller & Gregory A. Wiseman. (2007) 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nuclear Medicine Communications 28:11, pages 834-841.
Crossref
Crossref
Andreas K. Buck, Clemens Kratochwil, Gerhard Glatting, Malik Juweid, Martin Bommer, Djurdja Tepsic, Andreas T. J. Vogg, Torsten Mattfeldt, Bernd Neumaier, Peter Möller & Sven N. Reske. (2007) Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. European Journal of Nuclear Medicine and Molecular Imaging 34:11, pages 1775-1782.
Crossref
Crossref
S. Kako, K. Izutsu, Y. Ota, Y. Minatani, M. Sugaya, T. Momose, K. Ohtomo, Y. Kanda, S. Chiba, T. Motokura & M. Kurokawa. (2007) FDG-PET in T-cell and NK-cell neoplasms. Annals of Oncology 18:10, pages 1685-1690.
Crossref
Crossref
Yair Herishanu, Chava Perry, Rony Braunstein, Ur Metser, Odelia Goor, Ori Rogowski, Shlomo Berliner, Aaron Polliack & Elizabeth Naparstek. (2007) Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin?s lymphoma. European Journal of Haematology 79:2, pages 150-154.
Crossref
Crossref
Ken Herrmann, Hinrich A. Wieder, Andreas K. Buck, Marion Schöffel, Bernd-Joachim Krause, Falko Fend, Tibor Schuster, Christian Meyer zum Büschenfelde, Hans-Jürgen Wester, Justus Duyster, Christian Peschel, Markus Schwaiger & Tobias Dechow. (2007) Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma. Clinical Cancer Research 13:12, pages 3552-3558.
Crossref
Crossref
Ronan Swords, John Bruzzi & Francis Giles. (2007) Recent advances in the diagnosis and therapy of richter’s syndrome. Medical Oncology 24:1, pages 17-32.
Crossref
Crossref
Anna M. Kirby & N. George Mikhaeel. (2007) The role of FDG PET in the management of lymphoma: what is the evidence base?. Nuclear Medicine Communications 28:5, pages 335-354.
Crossref
Crossref
K.A. Wood, P.J. Hoskin & M.I. Saunders. (2007) Positron Emission Tomography in Oncology: A Review. Clinical Oncology 19:4, pages 237-255.
Crossref
Crossref
Norbert AvrilDavid Propper. (2007) Functional PET imaging in cancer drug development. Future Oncology 3:2, pages 215-228.
Crossref
Crossref
K. Strobel, N.G. Schaefer, C. Renner, P. Veit-Haibach, D. Husarik, A.Y. Koma & T.F. Hany. (2007) Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose–positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients?. Annals of Oncology 18:4, pages 658-664.
Crossref
Crossref
Ching-yee Oliver Wong, Joseph Thie, Kelly J. Parling-Lynch, Dana Zakalik, Regina H. Wong, Marianne Gaskill, Jeffrey H. Margolis, Jack Hill, Ammar Sukari, Surya Chundru, Darlene Fink-Bennett & Conrad Nagle. (2006) Investigating the Existence of Quantum Metabolic Values in Non-Hodgkin’s Lymphoma by 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography. Molecular Imaging and Biology 9:1, pages 43-49.
Crossref
Crossref
Pier Luigi Zinzani, Gerardo Musuraca, Lapo Alinari, Stefano Fanti, Monica Tani, Vittorio Stefoni, Enrica Marchi, Mariapaola Fina, Cinzia Pellegrini, Paolo Castellucci, Mohsen Farsad & Michele Baccarani. (2007) Predictive Role of Positron Emission Tomography in the Outcome of Patients with Follicular Lymphoma. Clinical Lymphoma and Myeloma 7:4, pages 291-295.
Crossref
Crossref
. 2007. Oncologic Imaging. Oncologic Imaging
172
183
.
L. Kostakoglu, M. Coleman & S. J. Goldsmith. 2007. Clinical Nuclear Medicine. Clinical Nuclear Medicine
322
346
.
Wolfgang A. Weber. 2007. In Vivo Imaging of Cancer Therapy. In Vivo Imaging of Cancer Therapy
103
120
.
K. Namberger & R. Greil. (2006) The Role of Imaging in Malignant Lymphoma: A Critical View on PET Scanning in Current Clinical Practice. Imaging Decisions MRI 10:4, pages 22-31.
Crossref
Crossref
Gary J.R Cook, M. N Maisey, M. N Maisey & Vaseem Chengazi. 2006. Clinical Nuclear Medicine. Clinical Nuclear Medicine
761
762
.
Shannon T. Kahn, Christopher Flowers, Mary Jo Lechowicz, Kathryn Hollenbach & Peter A.S. Johnstone. (2006) Value of PET restaging after chemotherapy for non-Hodgkin’s lymphoma: Implications for consolidation radiotherapy. International Journal of Radiation Oncology*Biology*Physics 66:4, pages 961-965.
Crossref
Crossref
Solène Querellou, Frédéric Valette, Caroline Bodet-Milin, Aurore Oudoux, Thomas Carlier, Jean-Luc Harousseau, Jean-François Chatal & Olivier Couturier. (2006) FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease. Annals of Hematology 85:11, pages 759-767.
Crossref
Crossref
Tristan Barrett, Peter L. Choyke & Hisataka Kobayashi. (2006) Imaging of the lymphatic system: new horizons. Contrast Media & Molecular Imaging 1:6, pages 230-245.
Crossref
Crossref
Laurie H. Sehn & Joseph M. Connors. (2006) Treatment of Diffuse Large B-Cell Lymphoma: A Risk-Based Approach. Clinical Lymphoma and Myeloma 7, pages S14-S19.
Crossref
Crossref
P.L. Zinzani, M. Tani, S. Fanti, L. Alinari, G. Musuraca, E. Marchi, V. Stefoni, P. Castellucci, M. Fina, M. Farshad, S. Pileri & M. Baccarani. (2006) Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Annals of Oncology 17:8, pages 1296-1300.
Crossref
Crossref
Regiane S. Andrade, Dwight E. Heron, Berna Degirmenci, Pedro A.A. Filho, Barton F. Branstetter, Raja R. Seethala, Robert L. Ferris & Norbert Avril. (2006) Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. International Journal of Radiation Oncology*Biology*Physics 65:5, pages 1315-1322.
Crossref
Crossref
Clyde D. Ford, Frank Gabor, Ross Morgan & Bashar Dabbas. (2006) False-Positive Restaging PET Scans Involving the Spleen in Two Patients With Aggressive Non-Hodgkin Lymphoma. Clinical Nuclear Medicine 31:7, pages 391-393.
Crossref
Crossref
Elka Miller, Ur Metser, Galia Avrahami, Rina Dvir, Dalia Valdman, Liat Ben Sira, Dror Sayar, Yoav Burstein, Amos Toren, Isaac Yaniv & Einat Even-Sapir. (2006) Role of 18F-FDG PET/CT in Staging and Follow-up of Lymphoma in Pediatric and Young Adult Patients. Journal of Computer Assisted Tomography 30:4, pages 689-694.
Crossref
Crossref
N. George Mikhaeel. (2006) Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. European Journal of Nuclear Medicine and Molecular Imaging 33:S1, pages 22-26.
Crossref
Crossref
Alain Luciani, Emmanuel Itti, Alain Rahmouni, Michel Meignan & Olivier Clement. (2006) Lymph node imaging: Basic principles. European Journal of Radiology 58:3, pages 338-344.
Crossref
Crossref
Sandip Basu & Narendra Nair. (2006) Is it time to incorporate quantitative functional imaging data, FDG PET in particular, into the response evaluation criteria in solid tumours?. Nuclear Medicine Communications 27:5, pages 413-416.
Crossref
Crossref
Michel Meignan, Corinne Haioun, Emmanuel Itti, Alain Rahmouni & Felix Reyes. (2006) Value of [18F]Fluorodeoxyglucose–Positron Emission Tomography in Managing Adults with Aggressive Non-Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma 6:4, pages 306-313.
Crossref
Crossref
Martin HutchingsAnnika LoftMads HansenLars Møller PedersenThora BuhlJesper JurlanderSimon BuusSusanne KeidingFrancesco D'AmoreAnne-Marie BoesenAnne Kiil BerthelsenLena Specht. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:1, pages 52-59.
Crossref
Crossref
Tam??s Gy??rke, Thomas Zajic, Alexander Lange, Oliver Sch??fer, Ernst Moser, Ern?? Mak??Ingo Brink. (2006) Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nuclear Medicine Communications 27:1, pages 17-24.
Crossref
Crossref
Guy Jerusalem & Roland Hustinx. 2006. The Lymphomas. The Lymphomas
189
202
.
Sarah J. Vinnicombe & Rodney H. Reznek. 2006. The Lymphomas. The Lymphomas
167
188
.
Lale Kostakoglu & Stanley J. Goldsmith. 2006. Hodgkin’s and Non-Hodgkin’s Lymphoma. Hodgkin’s and Non-Hodgkin’s Lymphoma
363
412
.
Guy H. M. Jerusalem, Roland Hustinx & Pierre Rigo. 2006. Positron Emission Tomography. Positron Emission Tomography
125
145
.
Sharon F. Hain. 2006. Positron Emission Tomography. Positron Emission Tomography
217
231
.
Daniel N. Chatzifotiadis, Julia W. Buchanan & Richard L. Wahl. 2006. Oncology. Oncology
449
483
.
John BibbRobert HromasIan Rabinowitz. (2005) A Bayesian Approach to a Patient With a Residual Mass After Treatment for Non-Hodgkin's Lymphoma of the Thyroid. Journal of Clinical Oncology 23:34, pages 8911-8913.
Crossref
Crossref
Richard Wahl. 2005. Atlas of Clinical Positron Emission Tomography 2nd Edition. Atlas of Clinical Positron Emission Tomography 2nd Edition
119
148
.
N.G. Mikhaeel, M. Hutchings, P.A. Fields, M.J. O'Doherty & A.R. Timothy. (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Annals of Oncology 16:9, pages 1514-1523.
Crossref
Crossref
M.J. Reinhardt, C. Herkel, C. Altehoefer, J. Finke & E. Moser. (2005) Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?. Annals of Oncology 16:9, pages 1524-1529.
Crossref
Crossref
Amir H. Khandani & Richard L. Wahl. (2005) Applications of PET in Liver Imaging. Radiologic Clinics of North America 43:5, pages 849-860.
Crossref
Crossref
Corinne HaiounEmmanuel IttiAlain RahmouniPauline BriceJean-Didier RainKarim BelhadjPhilippe GaulardLaurent GarderetEric LepageFelix ReyesMichel Meignan. (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:4, pages 1376-1381.
Crossref
Crossref
M. Hutchings, N.G. Mikhaeel, P.A. Fields, T. Nunan & A.R. Timothy. (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Annals of Oncology 16:7, pages 1160-1168.
Crossref
Crossref
Guy Jerusalem, Roland Hustinx, Yves Beguin & Georges Fillet. (2005) Evaluation of Therapy for Lymphoma. Seminars in Nuclear Medicine 35:3, pages 186-196.
Crossref
Crossref
Catherine Burton. (2005) A 61-Year-Old Man with Dyspepsia and Weight Loss. PLoS Medicine 2:6, pages e154.
Crossref
Crossref
Chaitanya Divgi. (2005) Imaging: Staging and evaluation of lymphoma using nuclear medicine. Seminars in Oncology 32, pages 11-18.
Crossref
Crossref
Toshiki Kazama, Silvana C. Faria, Vithya Varavithya, Sith Phongkitkarun, Hisao Ito & Homer A. Macapinlac. (2005) FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls. RadioGraphics 25:1, pages 191-207.
Crossref
Crossref
Norbert E. Avril & Wolfgang A. Weber. (2005) Monitoring response to treatment in patients utilizing PET. Radiologic Clinics of North America 43:1, pages 189-204.
Crossref
Crossref
Annick D. Van den Abbeele, David A. Israel, Stanislav Lechpammer & Ramsey D. Badawi. 2005. Tumor Ablation. Tumor Ablation
121
134
.
Rakesh Kumar, Ivan Maillard, Stephen J. Schuster & Abass Alavi. (2004) Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiologic Clinics of North America 42:6, pages 1083-1100.
Crossref
Crossref
Martin Hutchings, Annika I. Eigtved & Lena Specht. (2004) FDG-PET in the clinical management of Hodgkin lymphoma. Critical Reviews in Oncology/Hematology 52:1, pages 19-32.
Crossref
Crossref
Catherine Burton, Peter Ell & David Linch. (2004) The role of PET imaging in lymphoma. British Journal of Haematology 126:6, pages 772-784.
Crossref
Crossref
Ora Israel, Zohar Keidar & Rachel Bar-Shalom. (2004) Positron emission tomography in the evaluation of lymphoma. Seminars in Nuclear Medicine 34:3, pages 166-179.
Crossref
Crossref
Fernando Arias-Mendoza, Mitchell R Smith & Truman R Brown. (2004) Predicting treatment response in non-Hodgkin’s lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine1. Academic Radiology 11:4, pages 368-376.
Crossref
Crossref
S. F. Hain & I. Fogelman. (2004) Recent Advances in Imaging Hepatocellular Carcinoma. The Cancer Journal 10:2, pages 121-127.
Crossref
Crossref
Yvette L Kasamon, Richard L Wahl & Lode J Swinnen. (2004) FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy. Current Opinion in Oncology 16:2, pages 100-105.
Crossref
Crossref
Ralph M. Meyer, Richard F. Ambinder & Sigrid Stroobants. (2004) Hodgkin’s Lymphoma: Evolving Concepts with Implications for Practice. Hematology 2004:1, pages 184-202.
Crossref
Crossref
Sheila Sheth & Elliot K. Fishman. 2004. Radiological Imaging in Hematological Malignancies. Radiological Imaging in Hematological Malignancies
139
158
.
BenoîT Mesurolle, Nobuyuki Tanaka, John Kosiuk, FrançOis Mignon & Sylvain Choquet. 2004. Radiological Imaging in Hematological Malignancies. Radiological Imaging in Hematological Malignancies
443
472
.
G J R Cook. (2003) Oncological molecular imaging: nuclear medicine techniques. The British Journal of Radiology 76:suppl_2, pages S152-S158.
Crossref
Crossref
Josée M. Zijlstra, Otto S. Hoekstra, Pieter G. H. M. Raijmakers, Emile F. I. Comans, Jacobus J.M. Van Der Hoeven, Gerrit J. J. Teule, A. Roelof Jonkhoff, Harm V Tinteren, Adriaan A. Lammertsma & Peter C. Huijgens. (2003)
18
FDG positron emission tomography versus
67
Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma
. British Journal of Haematology 123:3, pages 454-462.
Crossref
Crossref
Jonathan W. Friedberg & Vaseem Chengazi. (2003) PET Scans in the Staging of Lymphoma: Current Status. The Oncologist 8:5, pages 438-447.
Crossref
Crossref
Jennifer Klem, Kavita Maung, Angelia Gibson & Vinay K. Jain. (2003) Highlights From: 39th Annual Meeting of the American Society of Clinical Oncology;May 31 to June 3, 2003 Chicago, Illinois. Clinical Lymphoma 4:2, pages 73-78.
Crossref
Crossref
S.F. Hain & M.N. Maisey. (2003) Positron emission tomography for urological tumours. BJU International 92:2, pages 159-164.
Crossref
Crossref
Karoline Spaepen, Sigrid Stroobants, Gregor Verhoef & Luc Mortelmans. (2003) Positron emission tomography with [18F]FDG for therapy response monitoring in lymphoma patients. European Journal of Nuclear Medicine and Molecular Imaging 30:S1, pages S97-S105.
Crossref
Crossref
P. J. Hoskin. (2003) PET in lymphoma: what are the oncologist's needs?. European Journal of Nuclear Medicine and Molecular Imaging 30:S1, pages S37-S41.
Crossref
Crossref
Hirofumi Koga, Yoshio Matsuo, Masayuki Sasaki, Makoto Nakagawa, Koichiro Kaneko, Kazutaka Hayashi, Yasuo Kuwabara & Hiroshi Honda. (2003) Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma. Annals of Nuclear Medicine 17:4, pages 327-331.
Crossref
Crossref
M Schwaiger. (2002) Functional imaging for assessment of therapy. The British Journal of Radiology 75:suppl_9, pages S67-S73.
Crossref
Crossref
I. Ho Shon, M.J. O'Doherty & M.N. Maisey. (2002) Positron emission tomography in lung cancer. Seminars in Nuclear Medicine 32:4, pages 240-271.
Crossref
Crossref
M.J. O'Doherty, E.A. Macdonald, S.F. Barrington, N.G. Mikhaeel & S. Schey. (2002) Positron Emission Tomography in the Management of Lymphomas. Clinical Oncology 14:5, pages 415-426.
Crossref
Crossref
Sarah S Donaldson. (2002) Pediatric Hodgkin’s disease—up, up, and beyond. International Journal of Radiation Oncology*Biology*Physics 54:1, pages 1-8.
Crossref
Crossref
Masayuki Sasaki, Yasuo Kuwabara, Hirofumi Koga, Makoto Nakagawa, Tao Chen, Kouichirou Kaneko, Kazutaka Hayashi, Katsumasa Nakamura & Kouji Masuda. (2002) Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Annals of Nuclear Medicine 16:5, pages 337-345.
Crossref
Crossref
A. Trojan, M. Jermann, C. Taverna & T.F. Hany. (2002) Fusion PET–CT imaging of neurolymphomatosis. Annals of Oncology 13:5, pages 802-805.
Crossref
Crossref
P. J. Hoskin. (2002) FDG PET in the management of lymphoma: a clinical perspective. European Journal of Nuclear Medicine and Molecular Imaging 29:4, pages 449-451.
Crossref
Crossref
S F Barrington. (2001) Whole body applications of positron emission tomography in oncology. Imaging 13:3, pages 185-196.
Crossref
Crossref
. (2001) Current Awareness. Hematological Oncology 19:3, pages 121-128.
Crossref
Crossref
M. J. OʼDOHERTY. (2001) Editorial. Nuclear Medicine Communications 22:7, pages 737-739.
Crossref
Crossref